Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

S Nagao; P Harter; A Leary; C Cropet; S Pignata; K Fujiwara; AJG Martin; G Bogner; I Vergote; N Colombo; J Maenpaa; F Selle; B Schmalfeldt; G Scambia; EMG Alia; C Lefeuvre-Plesse; A Belau; A Lortholary; M Gropp-Meier; E Pujade-Lauraine; I Ray-Coquard

doi:10.1016/j.annonc.2022.10.212

Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

S Nagao
, P Harter
, A Leary
, C Cropet
, S Pignata
, K Fujiwara
, AJG Martin
, G Bogner
, I Vergote
, N Colombo
, J Maenpaa
, F Selle
, B Schmalfeldt
, G Scambia
, EMG Alia
, C Lefeuvre-Plesse
, A Belau
, A Lortholary
, M Gropp-Meier
, E Pujade-Lauraine

I Ray-Coquard

Research output: Contribution to journal › Abstract (Journal) › peer-review

5 Citations (Web of Science)

Original language	English
Pages (from-to)	S1503-S1504
Journal	ANNALS OF ONCOLOGY
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.10.212
Publication status	Published - 2022
Event	ESMO Asia Congress - Singapore, SINGAPORE Duration: 2 Dec 2022 → 4 Dec 2022

Access to Document

10.1016/j.annonc.2022.10.212

Cite this

Nagao, S., Harter, P., Leary, A., Cropet, C., Pignata, S., Fujiwara, K., Martin, AJG., Bogner, G., Vergote, I., Colombo, N., Maenpaa, J., Selle, F., Schmalfeldt, B., Scambia, G., Alia, EMG., Lefeuvre-Plesse, C., Belau, A., Lortholary, A., Gropp-Meier, M., ... Ray-Coquard, I. (2022). Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ANNALS OF ONCOLOGY , 33, S1503-S1504. https://doi.org/10.1016/j.annonc.2022.10.212

Nagao, S ; Harter, P ; Leary, A et al. / Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). In: ANNALS OF ONCOLOGY 2022 ; Vol. 33. pp. S1503-S1504.

@article{9bfc88afcf3e4422a6bbf534893502f4,

title = "Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)",

author = "S Nagao and P Harter and A Leary and C Cropet and S Pignata and K Fujiwara and AJG Martin and G Bogner and I Vergote and N Colombo and J Maenpaa and F Selle and B Schmalfeldt and G Scambia and EMG Alia and C Lefeuvre-Plesse and A Belau and A Lortholary and M Gropp-Meier and E Pujade-Lauraine and I Ray-Coquard",

year = "2022",

doi = "10.1016/j.annonc.2022.10.212",

language = "English",

volume = "33",

pages = "S1503--S1504",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "ESMO Asia Congress ; Conference date: 02-12-2022 Through 04-12-2022",

}

Nagao, S, Harter, P, Leary, A, Cropet, C, Pignata, S, Fujiwara, K, Martin, AJG, Bogner, G, Vergote, I, Colombo, N, Maenpaa, J, Selle, F, Schmalfeldt, B, Scambia, G, Alia, EMG, Lefeuvre-Plesse, C, Belau, A, Lortholary, A, Gropp-Meier, M, Pujade-Lauraine, E & Ray-Coquard, I 2022, 'Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)', ANNALS OF ONCOLOGY , vol. 33, pp. S1503-S1504. https://doi.org/10.1016/j.annonc.2022.10.212

Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). / Nagao, S; Harter, P; Leary, A et al.
In: ANNALS OF ONCOLOGY , Vol. 33, 2022, p. S1503-S1504.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

AU - Nagao, S

AU - Harter, P

AU - Leary, A

AU - Cropet, C

AU - Pignata, S

AU - Fujiwara, K

AU - Martin, AJG

AU - Bogner, G

AU - Vergote, I

AU - Colombo, N

AU - Maenpaa, J

AU - Selle, F

AU - Schmalfeldt, B

AU - Scambia, G

AU - Alia, EMG

AU - Lefeuvre-Plesse, C

AU - Belau, A

AU - Lortholary, A

AU - Gropp-Meier, M

AU - Pujade-Lauraine, E

AU - Ray-Coquard, I

PY - 2022

Y1 - 2022

U2 - 10.1016/j.annonc.2022.10.212

DO - 10.1016/j.annonc.2022.10.212

M3 - Abstract (Journal)

SN - 0923-7534

VL - 33

SP - S1503-S1504

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - ESMO Asia Congress

Y2 - 2 December 2022 through 4 December 2022

ER -

Nagao S, Harter P, Leary A, Cropet C, Pignata S, Fujiwara K et al. Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ANNALS OF ONCOLOGY . 2022;33:S1503-S1504. doi: 10.1016/j.annonc.2022.10.212